Paper39147708
[Research Progress of Engineered Exosomes in the Treatment of Lung Cancer].
Yang W and 1 other. Zhongguo Fei Ai Za Zhi, 2024. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. [Research Progress of Engineered Exosomes in the Treatment of Lung Cancer]. Papers, record 39147708. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39147708
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Exosomes | Major topic |
| Lung Neoplasms | Major topic |
| Humans | |
| Animals |
Source PubMed
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34147721 | Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy. | Biomaterials | 2021 | https://conductscience.org/library/papers/34147721 | PubMed |
| 2 | 29434759 | miR-613 inhibits gastric cancer progression through repressing brain derived neurotrophic factor. | Exp Ther Med | 2018 | https://conductscience.org/library/papers/29434759 | PubMed |
| 3 | 22025255 | Neuropilin-1 expression in cancer and development. | J Pathol | 2012 | https://conductscience.org/library/papers/22025255 | PubMed |
| 4 | 33007840 | Radio-Resistance and DNA Repair in Pediatric Diffuse Midline Gliomas. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33007840 | PubMed |
| 5 | 29790681 | Multiple primary lung cancer: A literature review. | Adv Clin Exp Med | 2018 | https://conductscience.org/library/papers/29790681 | PubMed |
| 6 | 29339084 | miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer. | Cell Signal | 2018 | https://conductscience.org/library/papers/29339084 | PubMed |
| 7 | 35179953 | Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity. | Sci Adv | 2022 | https://conductscience.org/library/papers/35179953 | PubMed |
| 8 | 31289551 | High expression of miR-155 and miR-21 in the recurrence or metastasis of non-small cell lung cancer. | Oncol Lett | 2019 | https://conductscience.org/library/papers/31289551 | PubMed |
| 9 | 32150868 | Counteracting Radio-Resistance Using the Optimization of Radiotherapy. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32150868 | PubMed |
| 10 | 34506976 | Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. | Acta Biomater | 2021 | https://conductscience.org/library/papers/34506976 | PubMed |
| 11 | 36568253 | Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. | Front Oncol | 2022 | https://conductscience.org/library/papers/36568253 | PubMed |
| 12 | 31833519 | Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer. | Nanoscale | 2020 | https://conductscience.org/library/papers/31833519 | PubMed |
| 13 | 34560422 | M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. | Biomaterials | 2021 | https://conductscience.org/library/papers/34560422 | PubMed |
| 14 | 36922504 | Engineered exosomes from different sources for cancer-targeted therapy. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36922504 | PubMed |
| 15 | 6307529 | Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. | Cell | 1983 | https://conductscience.org/library/papers/6307529 | PubMed |
| 16 | 31746532 | Responsive Exosome Nano-bioconjugates for Synergistic Cancer Therapy. | Angew Chem Int Ed Engl | 2020 | https://conductscience.org/library/papers/31746532 | PubMed |
| 17 | 31122265 | The roles of glucose metabolic reprogramming in chemo- and radio-resistance. | J Exp Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31122265 | PubMed |
| 18 | 30030592 | Overview upon miR-21 in lung cancer: focus on NSCLC. | Cell Mol Life Sci | 2018 | https://conductscience.org/library/papers/30030592 | PubMed |
| 19 | 11373684 | Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. | Nature | 2001 | https://conductscience.org/library/papers/11373684 | PubMed |
| 20 | 31430455 | Cancer stem cell (CSC) resistance drivers. | Life Sci | 2019 | https://conductscience.org/library/papers/31430455 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41657802 | Immune checkpoint inhibitors combined with chemotherapy enhance coagulation activation and elevate venous thromboembolism risk in non-small cell lung cancer. | Am J Cancer Res | 2026 | https://conductscience.org/library/papers/41657802 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39147708
GET https://conductscience.org/api/papers/v1/39147708/references?page=2